Rectal diazepam gel for treatment of acute repetitive seizures

Robert L. Kriel, James C. Cloyd, John M. Pellock, Wendy G. Mitchell, James Cereghino, N. Paul Rosman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The purpose of these investigations was to determine from combined data the response to rectal diazepam (DZP) gel (Diastat [Athena Neurosciences, South San Francisco, CA]) in home treatment of children with episodes of acute repetitive seizures (ARS). A subset of patients aged 2-17 years were selected from two prospective placebo-controlled studies of children and adults. In both studies a prospective, double-blind, placebo-controlled design was used. The treatment groups (68 DZP; 65 placebo) did not differ significantly in age, race, seizure type or etiology, or in the median number of ARS episodes per month before study entry. DZP-treated children demonstrated a significant reduction in median seizure frequency compared with the placebo group (0.00 vs 0.25 seizures per hour, P = 0.001). Significantly more DZP-treated children remained seizure free during the observation period (40 vs 20, P = 0.001). Somnolence was the only adverse effect present significantly more often in the DZP-treated children (25.0% vs 7.7%, P = 0.0095). There were no instances of serious respiratory depression. Rectal DZP was demonstrated to be an effective and safe treatment to abort an episode of ARS in a child and, additionally, lessened the likelihood of seizure recurrence within the next 12 hours.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalPediatric Neurology
Volume20
Issue number4
DOIs
StatePublished - Apr 1999

Fingerprint

Diazepam
Seizures
Gels
Placebos
Therapeutics
San Francisco
Neurosciences
Respiratory Insufficiency
Observation
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Kriel, R. L., Cloyd, J. C., Pellock, J. M., Mitchell, W. G., Cereghino, J., & Rosman, N. P. (1999). Rectal diazepam gel for treatment of acute repetitive seizures. Pediatric Neurology, 20(4), 282-288. https://doi.org/10.1016/S0887-8994(98)00156-8

Rectal diazepam gel for treatment of acute repetitive seizures. / Kriel, Robert L.; Cloyd, James C.; Pellock, John M.; Mitchell, Wendy G.; Cereghino, James; Rosman, N. Paul.

In: Pediatric Neurology, Vol. 20, No. 4, 04.1999, p. 282-288.

Research output: Contribution to journalArticle

Kriel, RL, Cloyd, JC, Pellock, JM, Mitchell, WG, Cereghino, J & Rosman, NP 1999, 'Rectal diazepam gel for treatment of acute repetitive seizures', Pediatric Neurology, vol. 20, no. 4, pp. 282-288. https://doi.org/10.1016/S0887-8994(98)00156-8
Kriel, Robert L. ; Cloyd, James C. ; Pellock, John M. ; Mitchell, Wendy G. ; Cereghino, James ; Rosman, N. Paul. / Rectal diazepam gel for treatment of acute repetitive seizures. In: Pediatric Neurology. 1999 ; Vol. 20, No. 4. pp. 282-288.
@article{e7ca9aa42f9542c7b09eec15ae3e7157,
title = "Rectal diazepam gel for treatment of acute repetitive seizures",
abstract = "The purpose of these investigations was to determine from combined data the response to rectal diazepam (DZP) gel (Diastat [Athena Neurosciences, South San Francisco, CA]) in home treatment of children with episodes of acute repetitive seizures (ARS). A subset of patients aged 2-17 years were selected from two prospective placebo-controlled studies of children and adults. In both studies a prospective, double-blind, placebo-controlled design was used. The treatment groups (68 DZP; 65 placebo) did not differ significantly in age, race, seizure type or etiology, or in the median number of ARS episodes per month before study entry. DZP-treated children demonstrated a significant reduction in median seizure frequency compared with the placebo group (0.00 vs 0.25 seizures per hour, P = 0.001). Significantly more DZP-treated children remained seizure free during the observation period (40 vs 20, P = 0.001). Somnolence was the only adverse effect present significantly more often in the DZP-treated children (25.0{\%} vs 7.7{\%}, P = 0.0095). There were no instances of serious respiratory depression. Rectal DZP was demonstrated to be an effective and safe treatment to abort an episode of ARS in a child and, additionally, lessened the likelihood of seizure recurrence within the next 12 hours.",
author = "Kriel, {Robert L.} and Cloyd, {James C.} and Pellock, {John M.} and Mitchell, {Wendy G.} and James Cereghino and Rosman, {N. Paul}",
year = "1999",
month = "4",
doi = "10.1016/S0887-8994(98)00156-8",
language = "English (US)",
volume = "20",
pages = "282--288",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Rectal diazepam gel for treatment of acute repetitive seizures

AU - Kriel, Robert L.

AU - Cloyd, James C.

AU - Pellock, John M.

AU - Mitchell, Wendy G.

AU - Cereghino, James

AU - Rosman, N. Paul

PY - 1999/4

Y1 - 1999/4

N2 - The purpose of these investigations was to determine from combined data the response to rectal diazepam (DZP) gel (Diastat [Athena Neurosciences, South San Francisco, CA]) in home treatment of children with episodes of acute repetitive seizures (ARS). A subset of patients aged 2-17 years were selected from two prospective placebo-controlled studies of children and adults. In both studies a prospective, double-blind, placebo-controlled design was used. The treatment groups (68 DZP; 65 placebo) did not differ significantly in age, race, seizure type or etiology, or in the median number of ARS episodes per month before study entry. DZP-treated children demonstrated a significant reduction in median seizure frequency compared with the placebo group (0.00 vs 0.25 seizures per hour, P = 0.001). Significantly more DZP-treated children remained seizure free during the observation period (40 vs 20, P = 0.001). Somnolence was the only adverse effect present significantly more often in the DZP-treated children (25.0% vs 7.7%, P = 0.0095). There were no instances of serious respiratory depression. Rectal DZP was demonstrated to be an effective and safe treatment to abort an episode of ARS in a child and, additionally, lessened the likelihood of seizure recurrence within the next 12 hours.

AB - The purpose of these investigations was to determine from combined data the response to rectal diazepam (DZP) gel (Diastat [Athena Neurosciences, South San Francisco, CA]) in home treatment of children with episodes of acute repetitive seizures (ARS). A subset of patients aged 2-17 years were selected from two prospective placebo-controlled studies of children and adults. In both studies a prospective, double-blind, placebo-controlled design was used. The treatment groups (68 DZP; 65 placebo) did not differ significantly in age, race, seizure type or etiology, or in the median number of ARS episodes per month before study entry. DZP-treated children demonstrated a significant reduction in median seizure frequency compared with the placebo group (0.00 vs 0.25 seizures per hour, P = 0.001). Significantly more DZP-treated children remained seizure free during the observation period (40 vs 20, P = 0.001). Somnolence was the only adverse effect present significantly more often in the DZP-treated children (25.0% vs 7.7%, P = 0.0095). There were no instances of serious respiratory depression. Rectal DZP was demonstrated to be an effective and safe treatment to abort an episode of ARS in a child and, additionally, lessened the likelihood of seizure recurrence within the next 12 hours.

UR - http://www.scopus.com/inward/record.url?scp=0032910512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032910512&partnerID=8YFLogxK

U2 - 10.1016/S0887-8994(98)00156-8

DO - 10.1016/S0887-8994(98)00156-8

M3 - Article

VL - 20

SP - 282

EP - 288

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 4

ER -